SULF2 and neoplasm: After adjusting for age, sex, race, histologic type, stage, and neoadjuvant therapy, patients with ADC with SULF2 staining in tumor cells had a 31% increased risk of death (p = 0.65) (Table 4), and patients with SCC with SULF2 staining in tumor cells had an 89% decreased risk of death (p = 0.02) (Table 4).